Nordea Investment Management AB Makes New Investment in Insmed, Inc. $INSM

Nordea Investment Management AB acquired a new stake in Insmed, Inc. (NASDAQ:INSM) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 20,008 shares of the biopharmaceutical company’s stock, valued at approximately $3,492,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. CIBC Private Wealth Group LLC grew its stake in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares in the last quarter. Stone House Investment Management LLC acquired a new stake in Insmed in the 3rd quarter valued at about $29,000. SBI Securities Co. Ltd. raised its position in Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 166 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Insmed by 59.6% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 81 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. boosted its stake in shares of Insmed by 169.7% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 151 shares during the period.

Insmed Price Performance

Shares of NASDAQ:INSM opened at $145.30 on Friday. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $212.75. The firm has a market capitalization of $31.32 billion, a P/E ratio of -22.67 and a beta of 1.13. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. The company’s fifty day moving average price is $150.13 and its 200 day moving average price is $165.97.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The company had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business’s revenue was up 152.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.32) EPS. As a group, sell-side analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Leerink Partners lifted their price objective on shares of Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a research report on Tuesday. UBS Group cut their price target on Insmed from $223.00 to $215.00 and set a “buy” rating on the stock in a research note on Tuesday, January 6th. TD Cowen set a $241.00 price target on Insmed in a report on Thursday, December 18th. Mizuho upped their price objective on Insmed from $204.00 to $206.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Citigroup reiterated an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Insmed has a consensus rating of “Buy” and a consensus target price of $210.19.

Insider Transactions at Insmed

In other news, COO Roger Adsett sold 791 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $156.17, for a total value of $123,530.47. Following the completion of the sale, the chief operating officer directly owned 106,810 shares of the company’s stock, valued at approximately $16,680,517.70. This represents a 0.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO William Lewis sold 10,699 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $143.52, for a total transaction of $1,535,520.48. Following the transaction, the chief executive officer owned 301,185 shares in the company, valued at approximately $43,226,071.20. This trade represents a 3.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 189,651 shares of company stock worth $31,533,654 in the last three months. Corporate insiders own 3.00% of the company’s stock.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.